Study | Phase | Description | N = 153 |
---|---|---|---|
7401 | III | WBRT+(BCNU vs. MeCCNU+DTIC) | 38 (25%) |
7918 | III | WBRT+(BCNU vs. Misonidazole radiosensitizer & BCNU) | 9 (6%) |
8302 | III | Hyperfractionated and Accelerated RT + BCNU | 30 (20%) |
8409 | I/II | WBRT + AZQ (NSC-182986) | 1 (1%) |
9006 | III | BCNU + (Hyperfractionated RT vs. RT) | 32 (21%) |
9305 | III | +/-SRS followed by RT+BCNU | 3 (2%) |
9602 | II | RT + Taxol | 13 (8%) |
9806 | II | RT + Thalidomide | 27 (18%) |